Although formation of insoluble Aβ fragments in an amyloidogenic pathway by proteolytic cleavage of APP with β-and γ-secretases has been considered a key step in the pathogenesis of AD, tau increasingly emerged as an obligatory member of the neurodegenerative process [1] . Moreover, a number of reports found evidence for a relationship between Aβ and tau in AD [11] [12] [13] [14] .
Soluble Aβ oligomers facilitate wild-type human tau accumulation and hyperphosphorylation, leading to neuritic dystrophy [15] , and learning and memory deficits in transgenic mice [16] .
In addition, treatments with modulators of γ-secretase can reverse Aβ-associated tau pathology and reduce hyperphosphorylated tau levels in AD mouse models [17, 18] .
Interactions between tau and lipids also seem important in AD pathology. Phosphorylated tau was found in specific microdomains of plasma membrane called lipid rafts in neuronal cells exposed to Aβ peptides [19] , in lipid rafts of an AD mouse model, and in lipid rafts from AD brain [20] . Evidence indicates connections between lipids and Aβ as well. While proteolytic processing of APP is influenced by the lipid composition of cellular membranes, particularly with cholesterol and sphingolipids, Aβ in turn plays an essential role in regulating lipid homeostasis [21] .
Tau protein and axonal assembly and stability
Tau, a protein with multiple phosphorylation sites, belongs to the family of microtubuleassociated proteins. It is highly expressed in neurons, particularly in axons, with an essential role in the assembly of tubulin monomers into microtubules that are fundamental cellular structures for preservation of neuronal shape and axonal transport [22] . Therefore, tau plays a crucial role in the formation and maintenance of axons, microtubule dynamics, neurite outgrowth, and neuritic stability [23] .
Tau is encoded by a single gene, but due to alternative splicing of mRNA, several tau isoforms with differential affinity for microtubules are expressed in human brain in a developmental [24] , cell-specific, and pathology-related manner [25, 26] . In early developmental stages only the smallest tau isoform is expressed, while all tau isoforms are expressed during adulthood [27] . These isoforms differ by the presence of either three or four semiconserved repeat-regions in the C-terminus part of the molecule that form highly homologous microtubule-binding domain, and by the presence of two, one, or no inserts in the N-terminus part. Through these microtubule-binding repeats at the C-terminus, tau protein exerts its specific function in microtubule assembly and stabilization [28, 29] .
At the level of both mRNA and protein, a ratio of tau isoforms with 4 and 3 repeats (4R:3R) is approximately equal in healthy adult brain [30] . Alterations in 4R:3R ratio and mutations in the tau gene that cause amino acid substitutions lead to formation of intracellular inclusions consisting of highly phosphorylated tau with abnormal conformation [1, 31] .
Hyperphosphorylation of tau leads to toxicity and loss of function of the molecule are amino acids that can be phosphorylated [32] . The exact contribution of each phosphorylation sites or subsets of phosphorylation sites for normal tau function is still not completely understood. The normal tau contains 2-3 moles of phosphate per mole of protein, while in AD brain this phosphorylation stoichiometry is three to four times higher, with all isoforms being found in abnormally phosphorylated NFT [33] . By mass spectroscopy and antibody staining, the total number of identified phosphorylated residues in insoluble tau from AD brains is 45, which is significantly higher than the number of phosphorylated residues in soluble tau of healthy controls, and represents more than half of residues available for phosphorylation [1, 34, 35] .
Hyperphosphorylation results in dissociation of tau protein from microtubules and impairs its role in microtubule assembly and stabilization, leading to the loss of the normal content of microtubules [36] This ends in neuronal degeneration, synaptic loss, and ultimately cell death, a key end-point histopathological hallmark of AD [9, 30, 32, 40] .
In addition to phosphorylation-dependent loss of function, aberrant phosphorylation of tau induces tau-tau interactions and self-assembly into tangles of paired helical filaments that build up NFT inside neurons [41] . Development of NFT occurs in a stepwise manner, and the specific pattern of tau phosphorylation correlates with severity of neuronal cytopathology [42] . The appearance of pathological changes can be classified in three morphological stages: pre-neurofibrillary tangle, intra-, and extra neuronal fibrillary tangles [43] . NFT also appear in a stereotypical order, certain regions being affected before others [44] [45] [46] [47] [48] .
Tau can be phosphorylated by prolinedirected and non-proline directed kinases [49, 50] . with the progression of neurodegeneration [61] [62] [63] . Altered activity of both GSK-3 isozymes contributes to key neuropathological hallmarks of AD. While GSK-3α participates in APP processing and deposition of Aβ by regulating the activity of γ-secretase [64] , the other isoform GSK-3β is considered as the major tau kinase involved in hyperphosphorylation of tau protein [65, 66] . As previously explained, GSK-3β-mediated phosphorylation of tau reduces its affinity for microtubules, and also modulates axonal transport [65, 67] .
GSK-3β recognizes phosphorylated
Ser residues, and phosphorylates Ser and Thr residues in the vicinity of previously phosphorylated Ser residues. It requires priorphosphorylation by cdk5 in vitro [68] , while evidence for in vivo priming is still missing.
Studies on transgenic mice also suggested a crucial role of GSK-3β in AD pathogenesis [69] , and a role of cdk5 in elevation of tau hyperphosphorylation and NFT formation [70] .
Phosphorylation of tau by GSK-3β may promote formation of tangle-like filament morphology in cell-free models [71] . GSK-3β also mediates tau phosphorylation in cultured cell lines [72] , while overactivation of GSK-3 in animal model induces tau hyperphosphorylation together with AD-like cognitive effects such as impairment of spatial memory [73] . Most importantly, it was shown that Aβ oligomers enhance tau phosphorylation ( Figure 1 ) and compromise cell survival through the mechanism mediated by GSK-3β activation [12, 14, 69] , and neurons from tau-knockout mice are resistant to Aβ-induced toxicity [11] .
Moreover, it has been reported that GSK-3β
facilitate APP processing and generation of Aβ [74] . Interestingly, presenilin 1, a part of γ-secretase, brings tau and GSK-3β in close proximity as both tau and GSK-3β bind to the same region of presenilin 1 [75] . Altogether these observations suggest that GSK-3β plays a central role in the pathological progression of neurodegeneration in vivo, and points to its great potential as a target for therapeutic interventions in AD.
Inhibition of tau phosphorylation and pharmacological outcomes (Table 1) .
However, despite the overall reduction in phosphorylated tau, treatment with lithium failed to improve memory impairments in some studies [79] [80] [81] .
Regarding Aβ pathology, treatments with lithium resulted in contradictory outcomes.
While some studies showed reduced Aβ level and reduced plaques formation [74] , increased Aβ production [64] , as well as unchanged
Aβ production have been reported [77, 80] .
A more recent study on a double transgenic GSK-3β is the main kinase involved in phosphorylation of tau. By a mechanism that is dependent on GSK-3β, intracellular accumulation of Aβ may also contribute to tau hyperphosphorylation. In addition, Aβ affects production of ceramides by acting on sphingomyelinases, enzymes responsible for the catabolic degradation of sphingomyelin. Generated ceramides in turn increase production of Aβ acting on β-secretase, a key enzyme in the proteolytic processing of amyloid precursor protein (APP). BDNF and presenilin may modulate these interactions, particularly via the PI3-K/Akt signaling pathway. PI3-K activates Akt/protein kinase B, while activated Akt in turn phosphorylates GSK-3β and induces its inactivation and reduction in tau phosphorylation. by inhibiting cdk5 activity [97] . Irrespective of this controversial finding, it is evident that neuronal survival could be determined with very small shifts in ceramide metabolism [98] .
Sphingolipids in AD
Ceramides (Cer), the major molecules of sphingolipid metabolic pathways, are expressed in both neurons and astrocytes. -dependent neutral sphingomyelinase activity, and elicits sphingomyelin hydrolysis and Cer increase [98] . Endogenous Cer can also be generated by a de novo synthesis pathway.
Elevated basal level of particular species of Cer in serum is associated with a higher risk for developing AD [110] . Cer are increased approximately three times in brains from AD patients [108] , particularly in vulnerable regions [111] . Besides increased levels of Cer [112] , and affecting its molecular stability [117, 118] .
In turn, oligomeric soluble Aβ and fibrillar Aβ activates neutral and acidic sphingomyelinases [119, 120] . Hence, Aβ-dependent increase in ceramide levels leads to further increase in Aβ production ( Figure 1 ). In addition, upregulated sphingomyelinase correlates with increased tau hyperphosphorylation in AD brains [112] .
On the other hand, activation of SPT also might increase Cer levels and contribute to AD pathology. SPT consists of SPTLC1 and SPTLC2 subunits, and expression of both has been confirmed in senile plaques [121] .
Interaction of astroglia and neurons in sphingolipid metabolism and AD pathology SPT upregulation in astrocytes is implicated in upregulation of sphingomyelinase activity in neurons. Soluble products released from palmitic acid (PA)-activated human astroglia activates neutral sphyngomyelinase and increases Cer levels and cell death in primary neuronal cultures [122] . In particular, exposure to PA, the most common saturated fatty acid, increases endogenous Cer production in astroglia, which in turn is involved in both increased amyloidogenesis and tau hyperphosphorylation in neurons exposed to conditioned media from PA-treated astrocytes [118, 123] . As direct treatment of primary neurons with PA had no effect on the BACE1 activity and Aβ levels [124] in AD patients [126] . Likewise, treatment of neurons with conditioned media obtained from astroglia exposed to both free fatty acids and L-cycloserine was able to decrease levels of increased Aβ, hyperphosphorylated tau, and activated GSK-3β [118] . Other studies also linked Cer to tau phosphorylation. It was
shown that Cer modulate PP2A activity [127] , and increase tau phosphorylation by cdk5 at specific sites [128] . Beside direct impact on 
